Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of VELCADE® (Bortezomib) for Steroid Refractory Acute GVHD

NCT00408928 is registered in ClinicalTrials.gov with Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University as lead sponsor.

NCT NCT00408928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00408928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of VELCADE® (Bortezomib) for Steroid Refractory Acute GVHD
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2005
Completion date
September 30, 2009
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft-versus-host disease